UnitedHealthcare · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as non-formulary by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Non-formulary doesn't mean uncoverable. Most plans have a formulary-exception process: the appeal needs to show the formulary alternatives are inappropriate for your specific clinical situation.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-05-04

At a glance

Why is tirzepatide non-formulary on UHC?

Both Mounjaro and Zepbound sit on UHC's non-preferred or specialty tier on most OptumRx formularies in 2026. The formulary preferred GLP-1 is typically semaglutide (Wegovy/Ozempic) given UHC's contracts with Novo Nordisk.

How do I get tirzepatide covered when it's non-formulary?

Submit a formulary tier exception with documented clinical reason for tirzepatide specifically over semaglutide — failure on semaglutide, GIP-mediated mechanism advantage, or tolerability difference.

What clinical advantage matters for the appeal?

SURMOUNT-1 showed mean 22.5% weight loss with tirzepatide vs. 14.9% with semaglutide. For severe obesity (BMI ≥40) or comorbidities requiring aggressive weight loss, the magnitude difference is clinically relevant. Cite the trial.

Can I get tirzepatide first-line without trying semaglutide first?

Almost never — UHC denies first-line tirzepatide unless there's a specific contraindication to semaglutide (extremely rare). The practical path: document semaglutide failure first, then submit the tier exception.

What's the form requirement?

OptumRx Tier Exception form requires a Prescriber Statement of Medical Necessity with specific check-boxes. Free-text letters get bounced back as non-conforming.

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

Zepbound (obesity): BMI >=30 or >=27 with comorbidity. Mounjaro (T2DM): HbA1c >=7% despite metformin trial.

Source policy: Tirzepatide (Zepbound, Mounjaro) Prior Authorization

What works in the appeal

Step therapy: Document contraindications to required agents (phentermine: uncontrolled hypertension, cardiovascular disease, hyperthyroidism; topiramate: pregnancy risk, kidney stones, glaucoma; Contrave: uncontrolled hypertension, seizure disorder, eating disorders, opioid use). If prior trials exist, submit records showing 12+ week trial with inadequate response (<5% weight loss) or intolerable side effects. Clinical necessity: Cite FDA approval of Zepbound (tirzepatide) for chronic weight management in adults with BMI ≥30 or ≥27 with weight-related comorbidity (May 2023). Reference SURMOUNT-1 trial showing 15-21% weight loss vs 3% placebo. For patients with prediabetes or metabolic syndrome, emphasize cardiometabolic benefit and diabetes prevention (58% reduction in progression per DPP trial). Request expedited appeal if patient has failed/cannot tolerate step therapy agents due to medical contraindications.

The UnitedHealthcare angle on Tirzepatide

UHC's non-formulary status on tirzepatide is the rule, not the exception, in 2026. Both Mounjaro and Zepbound sit on UHC's non-preferred or specialty tier on most OptumRx formularies; the formulary preferred GLP-1 is typically semaglutide (Wegovy or Ozempic) given UHC's contracts with Novo Nordisk. The path is a formulary tier exception with documented clinical reason for tirzepatide specifically over semaglutide.

Winning arguments for UHC tier exceptions on tirzepatide:

Failure on semaglutide. If the patient tried Wegovy or Ozempic with inadequate response (<5% weight loss at 6 months for Wegovy; HbA1c not reaching target on Ozempic) or intolerable GI side effects despite dose titration to maximum tolerated dose, document trial dates and outcomes. UHC accepts this as step failure within GLP-1 class.
Tirzepatide-specific clinical advantage. SURMOUNT-1 demonstrated mean 22.5% weight loss with tirzepatide vs. 14.9% with semaglutide. For patients with severe obesity (BMI ≥40) or comorbidities requiring more aggressive weight loss, the magnitude difference matters clinically. Cite the trial — SURMOUNT-1 (NEJM 2022;387:205-216) for obesity, SURPASS-2 for T2DM.
GIP-mediated mechanism. Tirzepatide's dual GIP/GLP-1 receptor agonism is mechanistically distinct from pure GLP-1 agonists. Patients with persistent insulin resistance despite semaglutide may benefit from the GIP component. This is a clinical sophistication argument that lands well with specialist reviewers (endocrinology, obesity medicine).
Tolerability difference. Some patients tolerate tirzepatide better than semaglutide due to different titration kinetics (5mg weekly start vs. 0.25mg) or different GI side-effect profiles. Document specific symptom recurrence pattern on semaglutide.
Continuity of care. If the patient is stable on tirzepatide started before plan change, federal continuity protections under 45 CFR §156.122 for ACA-compliant plans require coverage continuation during the plan year.

For patients new to GLP-1 therapy, UHC will likely deny tier exception on grounds that semaglutide hasn't been tried. A first-line tirzepatide request faces uphill review — almost always denied unless there's a specific contraindication to semaglutide (extremely rare, typically only in trial-documented hypersensitivity).

The practical move: document semaglutide failure first, then submit the tier exception. Going direct rarely overturns. This is a sequencing strategy that maximizes approval rate.

The federal regulatory hook: ACA-compliant plans must have an exception process per 45 CFR §156.122. ERISA §503's expedited path applies for fills near-empty. 29 CFR §2560.503-1(g)(1)(iv) requires UHC to disclose all relevant documents on appeal request — demand the OptumRx Tier Exception decision-support document if the denial doesn't articulate why tirzepatide isn't medically necessary.

OptumRx procedural lever: the OptumRx Tier Exception form requires a Prescriber Statement of Medical Necessity with specific check-boxes. Use the form. Free-text letters get bounced back as non-conforming.

Closing tactical tip: include both the SURMOUNT clinical trial citation AND the patient's specific failure-on-semaglutide documentation in one packet — UHC's reviewers respond to the combination of population-level evidence + patient-specific failure.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other denial reasons for UnitedHealthcare Tirzepatide

denied as not medically necessary denied for failing step therapy denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.